Feed - Buzzberg

12:00
Aug 12 ◎

AMCR FY2026 Q4 Watch

Amcor plc (AMCR) FY2026 Q4 Earnings Call

BERY AMCR ▾

Peter Konieczny

Amcor's free cash flow was $200M below outlook due to higher-than-expected working capital (inventories and receivables) directly tied to the Middle East conflict, with $500M targeted for recovery over the next 12 months. — This indicates a forced inventory build in the supply chain due to conflict-driven inflation; the unwind represents a significant liquidity release and a potential leading indicator that order flows for converted resins may soften as destocking occurs.

"we realized $115 million of synergy bringing total fiscal 2026 synergies to $285 million. This is approximately 10% ahead of our initial year one expectations."

BERY WATCH

Peter Konieczny

Management frames calendar 2027 as the first clean year post-integration, with double-digit EPS growth driven by cost synergies, revenue synergies, and modest volume growth, signalling a positive outlook.

"this represents the first pretty much clean year, in quotes, after the combination of Amco and Berry"

AMCR WATCH

HIGH

12:00
May 06 ◎

AMCR FY2026 Q3 Watch

Amcor plc (AMCR) FY2026 Q3 Earnings Call

AMCR ▾

Peter Konietzny

Management frames FY26 as a synergy-driven earnings growth year, confirming and slightly exceeding prior targets; despite raising the free cash flow guide (lowering), EPS guidance is maintained and reinforced, suggesting confidence in the underlying earnings trajectory.

"We expect adjusted EPS to be in the range of $3.98 to $4.03 per share for fiscal year 2026, representing strong growth of roughly 12% at the midpoint, driven primarily by synergy realization."

AMCR WATCH

HIGH

22:30
Feb 03 ◎

AMCR FY2026 Q2 Watch

Amcor plc (AMCR) FY2026 Q2 Earnings Call

BERY NVO LLY AMCR ▾

Peter Konietze

Berry Acquisition integration is on track, with synergies accelerating to $55M in Q2 and total $93M in H1 2026, and management now has over $100M in annualized revenue wins directly attributable to the combination, nearly half of the original three-year target of $280M already locked in. — This indicates strong early execution on the M&A thesis, potentially derisking the deal's long-term value creation for shareholders.

"Annualized sales revenue from business wins directly linked to our combination with Berry now exceeds $100 million, a strong start to our original three-year target of $280 million."

BERY WATCH

Peter Konietze

Amcor has won a significant supply contract for a major global pharmaceutical customer's new oral GLP-1 therapy drug, supplying blister packaging in Europe and rigid containers in the US. — This signals a shift in the GLP-1 drug delivery market towards oral formats and indicates Amcor is capturing new demand, potentially benefiting from the secular growth trend even as it may be a headwind for other parts of its portfolio.

"Adding another example of those we discussed last quarter, our strength and supply chain and multi-format capabilities have enabled us to support a major global pharmaceutical customer as they launch the solid oral dose GLP-1 therapy drug."

NVO WATCH LLY WATCH

Peter Konietze

Management reaffirmed full-year guidance with a double-digit EPS growth forecast and plans to double free cash flow, driven by synergy capture and productivity gains. However, they did not signal an inflection in volumes, maintaining a cautiously optimistic but not bullish stance.

"The reality is we're operating in a market that is all single digits down. And while everybody is hoping that the environment will turn in the short term in the second half, we're approaching it very much consistent with what we've seen in"

AMCR WATCH

HIGH

Feed — Buzzberg